{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:12:08Z","timestamp":1792699928820,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,25]]},"DOI":"10.7759\/cureus.19046","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T06:18:28Z","timestamp":1635229108000},"source":"Crossref","is-referenced-by-count":7,"title":["Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes"],"prefix":"10.7759","author":[{"given":"Sarunporn","family":"Kamolvisit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supphamat","family":"Chirnaksorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hataikarn","family":"Nimitphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnuek","family":"Sungkanuparph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Global HIV & AIDS Statistics \u2014 Fact Sheet. (2021). Accessed. August 25, 2021: http:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60604-8","article-title":"Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration","volume":"384","author":"Smith CJ","year":"2014","unstructured":"Smith CJ, Ryom L, Weber R, et al.. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014, 384:241-48. 10.1016\/S0140-6736(14)60604-8","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30295-9","article-title":"Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies","volume":"6","author":"Althoff KN","year":"2019","unstructured":"Althoff KN, Gebo KA, Moore RD, et al.. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV. 2019, 6:e93-e104. 10.1016\/S2352-3018(18)30295-9","journal-title":"Lancet HIV"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1316471","article-title":"Nonalcoholic fatty liver disease and HIV infection","volume":"32","author":"Vallet-Pichard A","year":"2012","unstructured":"Vallet-Pichard A, Mallet V, Pol S. Nonalcoholic fatty liver disease and HIV infection. Semin Liver Dis. 2012, 32:158-66. 10.1055\/s-0032-1316471","journal-title":"Semin Liver Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.1.132","article-title":"Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors","volume":"28","author":"Jeric\u00f3 C","year":"2005","unstructured":"Jeric\u00f3 C, Knobel H, Montero M, et al.. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005, 28:132-37. 10.2337\/diacare.28.1.132","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282efad32","article-title":"Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection","volume":"21","author":"Wand H","year":"2007","unstructured":"Wand H, Calmy A, Carey DL, et al.. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS. 2007, 21:2445-53. 10.1097\/QAD.0b013e3282efad32","journal-title":"AIDS"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.10.018","article-title":"Expert panel review on nonalcoholic fatty liver disease in persons with human immunodeficiency virus","author":"Lake JE","year":"2020","unstructured":"Lake JE, Overton T, Naggie S, et al.. Expert panel review on nonalcoholic fatty liver disease in persons with human immunodeficiency virus. Clin Gastroenterol Hepatol. 2020, S1542-3565(20)31431-2. 10.1016\/j.cgh.2020.10.018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002484","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation","volume":"103","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation. Transplantation. 2019, 103:22-27. 10.1097\/TP.0000000000002484","journal-title":"Transplantation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i32.7236","article-title":"Transient elastography (FibroScan(\u00ae)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - where do we stand?","volume":"22","author":"Mikolasevic I","year":"2016","unstructured":"Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan(\u00ae)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - where do we stand?. World J Gastroenterol. 2016, 22:7236-51. 10.3748\/wjg.v22.i32.7236","journal-title":"World J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis","volume":"54","author":"Hernaez R","year":"2011","unstructured":"Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011, 54:1082-90. 10.1002\/hep.24452","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-016-0329-5","article-title":"Use of non-invasive testing to stage liver fibrosis in patients with HIV","volume":"13","author":"Matta B","year":"2016","unstructured":"Matta B, Lee TH, Patel K. Use of non-invasive testing to stage liver fibrosis in patients with HIV. Curr HIV\/AIDS Rep. 2016, 13:279-88. 10.1007\/s11904-016-0329-5","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001936","article-title":"Diagnostic accuracy of noninvasive markers of steatosis, NASH, and liver fibrosis in HIV-monoinfected individuals at risk of nonalcoholic fatty liver disease (NAFLD): results from the ECHAM study","volume":"80","author":"Lemoine M","year":"2019","unstructured":"Lemoine M, Assoumou L, De Wit S, et al.. Diagnostic accuracy of noninvasive markers of steatosis, NASH, and liver fibrosis in HIV-monoinfected individuals at risk of nonalcoholic fatty liver disease (NAFLD): results from the ECHAM study. J Acquir Immune Defic Syndr. 2019, 80:e86-94. 10.1097\/QAI.0000000000001936","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4137\/cmed.s5372","article-title":"Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review","volume":"3","author":"Desouza CV","year":"2010","unstructured":"Desouza CV, Shivaswamy V. Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review. Clin Med Insights Endocrinol Diabetes. 2010, 3:43-51. 10.4137\/cmed.s5372","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril F","year":"2018","unstructured":"Bril F, Kalavalapalli S, Clark VC, et al.. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. Clin Gastroenterol Hepatol. 2018, 16:558-566.e2. 10.1016\/j.cgh.2017.12.001","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi K","year":"2016","unstructured":"Cusi K, Orsak B, Bril F, et al.. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016, 165:305-15. 10.7326\/M15-1774","journal-title":"Ann Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.9270","article-title":"The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic fatty liver disease: a randomized double blinded clinical trial","volume":"13","author":"Razavizade M","year":"2013","unstructured":"Razavizade M, Jamali R, Arj A, Matini SM, Moraveji A, Taherkhani E. The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic fatty liver disease: a randomized double blinded clinical trial. Hepat Mon. 2013, 13:e9270. 10.5812\/hepatmon.9270","journal-title":"Hepat Mon"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal GP","year":"2008","unstructured":"Aithal GP, Thomas JA, Kaye PV, et al.. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008, 135:1176-84. 10.1053\/j.gastro.2008.06.047","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-ad09","article-title":"Addendum 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021","volume":"44","year":"2021","unstructured":"Addendum 2. Classification and diagnosis of diabetes. standards of medical care in diabetes-2021. Diabetes Care. 2021, 44:2182. 10.2337\/dc21-ad09","journal-title":"Diabetes Care"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-S011","article-title":"Standards of medical care in diabetes--2010","volume":"33","author":"American Diabetes Association","year":"2010","unstructured":"American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care. 2010, 33:S11-61. 10.2337\/dc10-S011","journal-title":"Diabetes Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25993","article-title":"Determination of reliability criteria for liver stiffness evaluation by transient elastography","volume":"57","author":"Boursier J","year":"2013","unstructured":"Boursier J, Zarski JP, de Ledinghen V, et al.. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013, 57:1182-91. 10.1002\/hep.25993","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera L","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019, 156:1264-1281.e4. 10.1053\/j.gastro.2018.12.036","journal-title":"Gastroenterology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2012.02781.x","article-title":"Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography","volume":"32","author":"Myers RP","year":"2012","unstructured":"Myers RP, Pollett A, Kirsch R, et al.. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012, 32:902-10. 10.1111\/j.1478-3231.2012.02781.x","journal-title":"Liver Int"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29724","article-title":"Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"68","author":"Younossi ZM","year":"2018","unstructured":"Younossi ZM, Loomba R, Rinella ME, et al.. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018, 68:361-71. 10.1002\/hep.29724","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00898-6","article-title":"Pharmacological treatment for non-alcoholic fatty liver disease","volume":"36","author":"Francque S","year":"2019","unstructured":"Francque S, Vonghia L. Pharmacological treatment for non-alcoholic fatty liver disease. Adv Ther. 2019, 36:1052-74. 10.1007\/s12325-019-00898-6","journal-title":"Adv Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12455","article-title":"Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: the impact of clinical and therapeutic factors over time","volume":"31","author":"Tripathi A","year":"2014","unstructured":"Tripathi A, Liese AD, Jerrell JM, Zhang J, Rizvi AA, Albrecht H, Duffus WA. Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: the impact of clinical and therapeutic factors over time. Diabet Med. 2014, 31:1185-93. 10.1111\/dme.12455","journal-title":"Diabet Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/1545109710373832","article-title":"Prevalence of and risk factors for pre-diabetes in HIV-1-infected patients in Bangkok, Thailand","volume":"9","author":"Srivanich N","year":"2010","unstructured":"Srivanich N, Ngarmukos C, Sungkanuparph S. Prevalence of and risk factors for pre-diabetes in HIV-1-infected patients in Bangkok, Thailand. J Int Assoc Physicians AIDS Care (Chic). 2010, 9:358-61. 10.1177\/1545109710373832","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi K","year":"2012","unstructured":"Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012, 142:711-725.e6. 10.1053\/j.gastro.2012.02.003","journal-title":"Gastroenterology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(00)80078-8","article-title":"A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus","volume":"23","author":"Chilcott J","year":"2001","unstructured":"Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther. 2001, 23:1792-823. 10.1016\/s0149-2918(00)80078-8","journal-title":"Clin Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort R","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K, et al.. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006, 355:2297-307. 10.1056\/NEJMoa060326","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/74530-pioglitazone-for-the-treatment-of-metabolic-associated-fatty-liver-disease-in-people-living-with-hiv-and-prediabetes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:35:54Z","timestamp":1707507354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/74530-pioglitazone-for-the-treatment-of-metabolic-associated-fatty-liver-disease-in-people-living-with-hiv-and-prediabetes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.19046","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,25]]}}}